Trial intelligence / Profile preview

Upadacitinib maintenance and long-term extension study in Crohn's disease

NL-OMON54751Phase 3Recruiting

Sponsor
AbbVie Inc.
Start
Oct 2018
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc.. Started Oct 2018; status: recruiting.

02

Drugs

upadacitinib
03

Conditions

Crohn's disease

Beyond the preview

Go deeper on NL-OMON54751.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON54751.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call